Hyperglycemia management in patients with posttransplantation diabetes

Endocrine Practice

Volumn 22, Issue 4, 2016, Pages 454-465

  Galindo, Rodolfo J ^a   Fried, Martin ^b   Breen, Tracy ^a   Tamler, Ronald ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; MAMMALIAN TARGET OF RAPAMYCIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; RAPAMYCIN; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TACROLIMUS; VILDAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SULFONYLUREA DERIVATIVE;

BLADDER CANCER; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIET SUPPLEMENTATION; GRAFT REJECTION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY GRAFT; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; ORGAN TRANSPLANTATION; PERSONALIZED MEDICINE; POSTOPERATIVE COMPLICATION; REVIEW; ADVERSE EFFECTS; CLASSIFICATION; DIABETES MELLITUS, TYPE 2; STATISTICS AND NUMERICAL DATA;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; ORGAN TRANSPLANTATION; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84982899819     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP151039.RA     Document Type: Review

References (79)

1. Wauters RP, Cosio FG, Suarez Fernandez ML, Kudva Y, Shah P, Torres VE. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation. 2012;94:377-382.
2. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care. 2002;25:583-592.
3. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007;83: 1027-1034.
4. Starzl TE. Post-operative care and surgical complications. In: Experience in Renal Transplantation. Philadelphia, PA: Saunders; 1964: 117.
5. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75:SS3-S24.
6. Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14:1992-2000.
7. American Diabetes Association. (2) Classification and Diagnosis of Diabetes. Diabetes Care. 2015;38:S8-S16.
8. Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation. 2013;96:726-731.
9. Shabir S, Jham S, Harper L, et al. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. Transpl Int. 2013;26:315-321.
10. Porrini EL, Díaz JM, Moreso F, et al. Clinical evolution of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2015 Nov 3. [Epub ahead of print] DOI: 10. 1093/ndt/gfv368
11. Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009;4:853-859.
12. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23:739-749.
13. Hecking M, Werzowa J, Haidinger M, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant. 2013;28:550-666.
14. Delaunay F, Khan A, Cintra A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest. 1997;100:2094-2098.
15. Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci. 1976;271:202-210.
16. Midtvedt K, Hjelmesæth J, Hartmann A, et al. Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15: 3233-3239.
17. Boots JM, van Duijnhoven EM, Christiaans MHL, Wolffenbuttel BH, Van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221-227.
18. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006:CD005161.
19. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Criag JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005:CD003961.
20. Penninga L, Penninga EI, Møller CH, Iversen M, Steinbrüchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013;5: CD008817.
21. van Hooff JP, Christiaans MHL, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2004;19 Suppl 6:vi8-vi12.
22. Duijnhoven EM, Boots JMM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12:583-588.
23. Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem. 2010;285:40050-40059.
24. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19:1411-1418.
25. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128-3135.
26. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic b-cells and a review of the underlying molecular mechanisms. Diabetes. 2013;62: 2674-2682.
27. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16-38.
28. Hermayer KL, Egidi MF, Finch NJ, et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab. 2012;97:4399-4406.
29. Wallia A, Parikh ND, O'Shea-Mahler E, et al. Glycemic control by a glucose management service and infection rates after liver transplantation. Endocrine Pract. 2011;17:546-551.
30. Garcia C, Wallia A, Gupta S, et al. Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients. Clin Transplant. 2013;27:444-454.
31. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-1131.
32. American Diabetes Association. (13) Diabetes care in the hospital, nursing home, and skilled nursing facility. Diabetes Care. 2015;38:S80-S85.
33. Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9-16.
34. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
35. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
36. American Diabetes Association. (6) Glycemic Targets. Diabetes Care. 2015;38:S33-S40.
37. U.S. Renal Data System Annual Data. Medications for diabetes control in the first six months post-transplant, 2009-2011. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, 2013. Available at: http://www.usrds.org/atlas.aspx.
38. Werzowa J, Hecking M, Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation. 2013;95:456-462.
39. Bonato V, Barni R, Cataldo D, et al. Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. Transplant Proc. 2008;40: 1888-1890.
40. Hricik DE. Metabolic syndrome in kidney transplantation: Management of risk factors. Clin J Am Soc Nephrol. 2011; 6:1781-1785.
41. Alexander JW, Metze TJ, McIntosh MJ, et al. The influence of immunomodulatory diets on transplant success and complications. Transplantation. 2005;79:460-465.
42. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008;85:353-358.
43. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996; 334:574-579.
44. Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med. 2014;371:1547-1548.
45. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668-2675.
46. Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14:979-984.
47. Soliman AR, Fathy A, Khashab S, Shaheen N, Soliman MA. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant. Exp Clin Transplant. 2013;11:494-498.
48. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004; 351:1106-1118.
49. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136.
50. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129-137.
51. Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;78:258-273.
52. Luther P, Baldwin D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004;4:2135-2138.
53. Baldwin D Jr, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation. 2004;77:1009-1014.
54. Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation. 2005;80: 1402-1405.
55. Pietruck F, Kribben A, Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int. 2005;18: 483-486.
56. Rizvi AA, Bowman MA. Thiazolidinedione therapy in a patient with diabetes after transplantation. Endocrine Pract. 2002;8:287-291.
57. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231-1245.
58. Sagedal S, Asberg A, Hartmann A, Bergan S, Berg KJ. Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Clin Transplant. 1998;12:553-556.
59. Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med. 2014;174:1605-1612.
60. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metabol. 2005; 90:501-506.
61. Tuerk TR, Bandur S, Nuernberger J, et al. Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. Clin Nephrol. 2008;70:26-32.
62. Blicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes & Metabolism. 2006;32: 113-120.
63. Schumacher S, Abbasi I, Weise D, et al. Single-and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001;57:147-152.
64. Turk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006;6:842-846.
65. Voytovich MH, Haukereid C, Hjelmesaeth J, Hartmann A, Løvik A, Jenssen T. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin Transplant. 2007;21:246-251.
66. Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-IV inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine. 2014;46:406-419.
67. Shirakawa J, Amo K, Ohminami H, et al. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 2011; 286:25467-25476.
68. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2041-2047.
69. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156.
70. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment. N Engl J Med. 2014;370:794-797.
71. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
72. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-242.
73. Strøm-Halden TA, Åsberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant. 2014;29:926-933.
74. Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care. 2013;36:e171-E172.
75. Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab. 2013;17:S203-S205.
76. Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation - a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014;14:115-123.
77. Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014;2014:617-638.
78. Pinelli NR, Nemerovski CW, Koelling TM. Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report. Transplant Proc. 2011;43:2113-2115.
79. Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011;92:e56-e57.